SUNPHARMA

Sun Pharmaceutical Industries Share Price

₹1,798.90 +3.6 (0.2%)

25 Nov, 2024 20:49

SIP TrendupStart SIP in SUNPHARMA

Start SIP

Performance

  • Low
  • ₹1,784
  • High
  • ₹1,830
  • 52 Week Low
  • ₹1,185
  • 52 Week High
  • ₹1,960
  • Open Price₹1,806
  • Previous Close₹1,795
  • Volume3,137,448

Investment Returns

  • Over 1 Month -2.7%
  • Over 3 Month + 1.3%
  • Over 6 Month + 21%
  • Over 1 Year + 50.48%
SIP Lightning

Smart Investing Starts Here Start SIP with Sun Pharmaceutical Industries for Steady Growth!

Invest Now

Sun Pharmaceutical Industries Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 39
  • PEG Ratio
  • 1.3
  • Market Cap Cr
  • 431,616
  • P/B Ratio
  • 6.4
  • Average True Range
  • 42.94
  • EPS
  • 46.72
  • Dividend Yield
  • 0.8
  • MACD Signal
  • -22.32
  • RSI
  • 45.44
  • MFI
  • 56.11

Sun Pharmaceutical Industries Financials

Sun Pharmaceutical Industries Technicals

EMA & SMA

Current Price
₹1,798.90
+ 3.6 (0.2%)
pointer
  • stock-down_img
  • Bullish Moving Average 10
  • stock-up_img
  • Bearish Moving Average 6
  • 20 Day
  • ₹1,809.57
  • 50 Day
  • ₹1,820.97
  • 100 Day
  • ₹1,770.93
  • 200 Day
  • ₹1,650.86

Resistance and Support

1804.35 Pivot Speed
  • R3 1,870.40
  • R2 1,850.20
  • R1 1,824.55
  • S1 1,778.70
  • S2 1,758.50
  • S3 1,732.85

What's your outlook on Sun Pharmaceutical Industries?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Sun Pharmaceutical Industries Ltd. is one of the largest pharmaceutical companies globally, specializing in generic and specialty medicines. It provides treatments across various therapeutic areas, including dermatology, oncology, neurology, and cardiology, serving patients in over 100 countries.

Sun Pharm.Industries has an operating revenue of Rs. 50,307.74 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 23% is great, ROE of 15% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 8% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 8% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 88 which is a GOOD score indicating consistency in earnings, a RS Rating of 67 which is FAIR indicating the recent price performance, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 36 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Sun Pharmaceutical Industries Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-28 Quarterly Results
2024-08-01 Quarterly Results
2024-05-22 Audited Results & Final Dividend
2024-01-31 Quarterly Results & Interim Dividend
2023-11-01 Quarterly Results
Date Purpose Remarks
2024-07-12 FINAL Rs.5.00 per share(500%)Final Dividend
2024-02-09 INTERIM Rs.8.50 per share(850%)Interim Dividend
2023-07-28 FINAL Rs.4.00 per share(400%)Final Dividend
2023-02-08 INTERIM Rs.7.50 per share(750%)Interim Dividend
2022-08-22 FINAL Rs.3.00 per share(300%)Final Dividend

Sun Pharmaceutical Industries F&O

Sun Pharmaceutical Industries Shareholding Pattern

54.48%
12.11%
4.94%
18.01%
0.03%
5.43%
5%

About Sun Pharmaceutical Industries

Active Pharma Ingredients (APIs) & variety of branded & generic formulations are produced, developed, & marketed by Sun Pharmaceuticals Industries Ltd. With global presence in trading & other ancillary activities, the corporation & its subsidiaries operate multiple manufacturing facilities across the globe, catering to the global market. It is India's biggest pharmaceutical corporation. Product Offerings: company manufactures a wide range of specialty & generic medications to address a variety of acute & chronic medical conditions. Generics, branded generics, specialist, hard-to-make technology-intensive pharmaceuticals, antiretrovirals, APIs, & intermediates are all part of its product line. It provides medications in every possible dose form, including liquids, tablets, sprays, ointments, creams, injectables, & capsules.

Indian Branded Generics: Largest Pharma business in India with 8.3% market share; Approximately 32% of revenues in FY23. Prescriptions with 12 classes of prescribers rank it first as well. In India, Sun Pharma leads the market in the chronic category. In India's top 300 pharmaceutical brands, it has 32 brands. Among other specialties, gastroenterology makes up 12%, neuropsychiatry 16%, & cardiology 18%.

US Business (~31% of revenues): This company ranks second in the US dermatology industry by prescriptions & joined the US pharma market in 1997. In terms of US generics, it ranks tenth. There were 616 ANDAs & 67 NDAs filed as of Q1FY24, & 519 ANDAs & 54 NDAs that had been authorized for a variety of therapies.

13 NDAs & 97 ANDAs are awaiting USFDA clearance. OTC, generics, & specialty markets are areas where corporations are well-represented. Liquids, creams, ointments, gels, sprays, injectables, tablets, capsules, drug-device combinations, & other products are sold by the company.
 

View More
  • NSE Symbol
  • SUNPHARMA
  • BSE Symbol
  • 524715
  • Chairman & Managing Director
  • Mr. Dilip S Shanghvi
  • ISIN
  • INE044A01036

Similar Stocks to Sun Pharmaceutical Industries

Sun Pharmaceutical Industries FAQs

Sun Pharmaceutical Industries share price is ₹1,798 As on 25 November, 2024 | 20:35

The Market Cap of Sun Pharmaceutical Industries is ₹431616.4 Cr As on 25 November, 2024 | 20:35

The P/E ratio of Sun Pharmaceutical Industries is 39 As on 25 November, 2024 | 20:35

The PB ratio of Sun Pharmaceutical Industries is 6.4 As on 25 November, 2024 | 20:35

Sun Pharmaceutical Industries (Sun Pharma) has an operating revenue of INR 36,704.43 Cr. on a trailing 12-month basis. Annual revenue growth of 3% is not great, Pre-tax margin of 8% is okay. Institutional holding has gone up in the last reported quarter is a positive sign. Analyst Recommendation on Sun Pharmaceutical Industries (Sun Pharma): HOLD

Dilip Shanghvi is the Managing Director of Sun Pharmaceutical Industries (Sun Pharma).

The ROE of Sun Pharmaceutical Industries (Sun Pharma) is 6% which is fair but needs improvement.

Sun Pharmaceutical Industries (Sun Pharma) has a reasonable debt to equity of 2%, which signals a healthy balance sheet.

The PE ratio of Sun Pharmaceutical Industries (Sun Pharma) is 81.5.

Metrics for analyzing sun pharma share price include: P/E Ratio, ROE, Profit Growth, as it Shows historical earnings growth.

To buy Sun Pharmaceuticals Industries Ltd shares, open a 5paisa account, fund it, search for Sun Pharmaceuticals Industries Ltd , place buy order, & confirm.

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23